Prostate Pathway Redesign
We will redesign the prostate pathway to rollout the 28-days to diagnosis standard, replacing the two-week wait / 62-day pathway to reflect new evidence on low-risk prostate cancer. At 28 days, patients will be placed on risk-stratified pathways and commence subsequent treatment within 31 days of shared decision to treat.
The cohort with low-risk prostate will have mpMRI scans to exclude prostate cancer. Any patients with a clinical suspicion of cancer will be referred on a 62-day pathway. This will remove the need for prostate biopsy.